Back
Rate this talk
Your peers have not rated this talk yet.
7-minute watch | Talk 6 of 8

EHA: Navigating CAR T in 2L DLBCL

CAR T in 2L DLBCL: A case study

Dr Eva Wagner-Drouet
SYMPOSIUM
EHA

Dr Eva Wagner-Drouet
University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany

Dr Eva Wagner-Drouet, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany, explores a case study where CAR T-cell therapy was used to support the 2L treatment of a patient diagnosed  with DLBCL and reviews aspects impacting treatment choice

Read more

Talks in this series

Prof. Bertram Glaß, Dr Keith Wilson, Dr Olalekan Oluwole, Dr Eva Wagner-Drouet and Lorna Warwick present at EHA (Navigating CAR T in 2L DLBCL)
1-minute watch | Talk 1 of 8
EHA: Navigating CAR T in 2L DLBCL
Series trailer
Prof. Bertram Glaß, Dr Keith Wilson, Dr Olalekan Oluwole, Dr Eva Wagner-Drouet and Lorna Warwick present at EHA (Navigating CAR T in 2L DLBCL)
1-minute watch
EHA: Navigating CAR T in 2L DLBCL

Series trailer

Prof. Bertram Glaß presents at EHA (Navigating CAR T in 2L DLBCL)
4-minute watch | Talk 2 of 8
Welcome and introduction
Prof. Bertram Glaß
Prof. Bertram Glaß presents at EHA (Navigating CAR T in 2L DLBCL)
4-minute watch

Welcome and introduction

Prof. Bertram Glaß

Dr Keith Wilson presents at EHA (Navigating CAR T in 2L DLBCL)
11-minute watch | Talk 3 of 8
Defining the unmet need in second-line DLBCL
Dr Keith Wilson
Dr Keith Wilson presents at EHA (Navigating CAR T in 2L DLBCL)
11-minute watch

Defining the unmet need in second-line DLBCL

Dr Keith Wilson

Dr Olalekan Oluwole presents at EHA (Navigating CAR T in 2L DLBCL)
11-minute watch | Talk 4 of 8
How has CAR T changed the second-line DLBCL treatment landscape?
Dr Olalekan Oluwole
Dr Olalekan Oluwole presents at EHA (Navigating CAR T in 2L DLBCL)
11-minute watch

How has CAR T changed the second-line DLBCL treatment landscape?

Dr Olalekan Oluwole

Prof. Bertram Glaß presents at EHA (Navigating CAR T in 2L DLBCL)
11-minute watch | Talk 5 of 8
How has CAR T changed the second-line DLBCL treatment landscape? Further studies
Prof. Bertram Glaß
Prof. Bertram Glaß presents at EHA (Navigating CAR T in 2L DLBCL)
11-minute watch

How has CAR T changed the second-line DLBCL treatment landscape? Further studies

Prof. Bertram Glaß

Dr Eva Wagner-Drouet presents at EHA (Navigating CAR T in 2L DLBCL)
7-minute watch | Talk 6 of 8
CAR T in 2L DLBCL: A case study
Dr Eva Wagner-Drouet
Dr Eva Wagner-Drouet presents at EHA (Navigating CAR T in 2L DLBCL)
7-minute watch

CAR T in 2L DLBCL: A case study

Dr Eva Wagner-Drouet

Lorna Warwick presents at EHA (Navigating CAR T in 2L DLBCL)
17-minute watch | Talk 7 of 8
Survivorship and CAR T
Ms Lorna Warwick
Lorna Warwick presents at EHA (Navigating CAR T in 2L DLBCL)
17-minute watch

Survivorship and CAR T

Ms Lorna Warwick

Prof. Bertram Glaß presents at EHA (Navigating CAR T in 2L DLBCL)
2-minute watch | Talk 8 of 8
Close
Prof. Bertram Glaß
Prof. Bertram Glaß presents at EHA (Navigating CAR T in 2L DLBCL)
2-minute watch

Close

Prof. Bertram Glaß

Prof. Bertram Glaß, Dr Keith Wilson, Dr Olalekan Oluwole, Dr Eva Wagner-Drouet and Lorna Warwick present at EHA (Navigating CAR T in 2L DLBCL)
1-minute watch | Talk 1 of 8
EHA: Navigating CAR T in 2L DLBCL
Series trailer
Prof. Bertram Glaß, Dr Keith Wilson, Dr Olalekan Oluwole, Dr Eva Wagner-Drouet and Lorna Warwick present at EHA (Navigating CAR T in 2L DLBCL)
1-minute watch
EHA: Navigating CAR T in 2L DLBCL

Series trailer

Prof. Bertram Glaß presents at EHA (Navigating CAR T in 2L DLBCL)
4-minute watch | Talk 2 of 8
Welcome and introduction
Prof. Bertram Glaß
Prof. Bertram Glaß presents at EHA (Navigating CAR T in 2L DLBCL)
4-minute watch

Welcome and introduction

Prof. Bertram Glaß

Dr Keith Wilson presents at EHA (Navigating CAR T in 2L DLBCL)
11-minute watch | Talk 3 of 8
Defining the unmet need in second-line DLBCL
Dr Keith Wilson
Dr Keith Wilson presents at EHA (Navigating CAR T in 2L DLBCL)
11-minute watch

Defining the unmet need in second-line DLBCL

Dr Keith Wilson

Dr Olalekan Oluwole presents at EHA (Navigating CAR T in 2L DLBCL)
11-minute watch | Talk 4 of 8
How has CAR T changed the second-line DLBCL treatment landscape?
Dr Olalekan Oluwole
Dr Olalekan Oluwole presents at EHA (Navigating CAR T in 2L DLBCL)
11-minute watch

How has CAR T changed the second-line DLBCL treatment landscape?

Dr Olalekan Oluwole

Prof. Bertram Glaß presents at EHA (Navigating CAR T in 2L DLBCL)
11-minute watch | Talk 5 of 8
How has CAR T changed the second-line DLBCL treatment landscape? Further studies
Prof. Bertram Glaß
Prof. Bertram Glaß presents at EHA (Navigating CAR T in 2L DLBCL)
11-minute watch

How has CAR T changed the second-line DLBCL treatment landscape? Further studies

Prof. Bertram Glaß

Dr Eva Wagner-Drouet presents at EHA (Navigating CAR T in 2L DLBCL)
7-minute watch | Talk 6 of 8
CAR T in 2L DLBCL: A case study
Dr Eva Wagner-Drouet
Dr Eva Wagner-Drouet presents at EHA (Navigating CAR T in 2L DLBCL)
7-minute watch

CAR T in 2L DLBCL: A case study

Dr Eva Wagner-Drouet

Lorna Warwick presents at EHA (Navigating CAR T in 2L DLBCL)
17-minute watch | Talk 7 of 8
Survivorship and CAR T
Ms Lorna Warwick
Lorna Warwick presents at EHA (Navigating CAR T in 2L DLBCL)
17-minute watch

Survivorship and CAR T

Ms Lorna Warwick

Prof. Bertram Glaß presents at EHA (Navigating CAR T in 2L DLBCL)
2-minute watch | Talk 8 of 8
Close
Prof. Bertram Glaß
Prof. Bertram Glaß presents at EHA (Navigating CAR T in 2L DLBCL)
2-minute watch

Close

Prof. Bertram Glaß

Interested in this topic?

Find more like this

Suggested for you

Explore suggested content tailored to your role within the CAR T-cell therapy journey

Job code: IHQ-UNB-4903 Date of preparation: October 2023
Job code: IHQ-UNB-4971 Date of preparation: October 2023

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

Reporting of side effects 
If you get any side effects, talk to your doctor or nurse. In Great Britain and Northern Ireland, you can also report side effects directly via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. You can also report side effects and quality complaints to Gilead. For information now how to report a side effect in another country, click here. By reporting side effects, you can help provide more information on the safety of this medicine.